This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Castle Biosciences, Inc. (CSTL) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Market Edge Highlights: Soundhound AI, Afya, Castle Biosciences, TriMas and Immersion
by Zacks Equity Research
Soundhound AI, Afya, Castle Biosciences, TriMas and Immersion are part of the Zacks Market Edge blog.
5 Top Small Cap Stocks to Buy Now
by Tracey Ryniec
How to screen for the best small cap stocks using the Zacks Rank.
All You Need to Know About Castle Biosciences (CSTL) Rating Upgrade to Strong Buy
by Zacks Equity Research
Castle Biosciences (CSTL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
by Nalak Das
We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.
Is Castle Biosciences (CSTL) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Castle Biosciences, Inc. (CSTL) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
Does Castle Biosciences (CSTL) Have the Potential to Rally 36.15% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 36.2% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Castle Biosciences (CSTL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Wall Street Analysts Predict a 36.09% Upside in Castle Biosciences (CSTL): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Castle Biosciences (CSTL) points to a 36.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Castle Biosciences (CSTL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Castle Biosciences (CSTL) delivered earnings and revenue surprises of 75.68% and 6.78%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Castle Biosciences, Inc. (CSTL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Castle Biosciences, Inc. (CSTL) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 88.10% and 28.85%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Insights Into Castle Biosciences, Inc. (CSTL) Q4: Wall Street Projections for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Castle Biosciences, Inc. (CSTL), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength?
by Zacks Equity Research
Alector (ALEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
How Much Upside is Left in Castle Biosciences, Inc. (CSTL)? Wall Street Analysts Think 67.01%
by Zacks Equity Research
The mean of analysts' price targets for Castle Biosciences, Inc. (CSTL) points to a 67% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q3 Earnings
by Zacks Equity Research
Although the revenue and EPS for Castle Biosciences, Inc. (CSTL) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alimera Sciences (ALIM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 85.37% and 4.25%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q2 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Castle Biosciences, Inc. (CSTL) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 30.69% and 15.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline
by Zacks Equity Research
Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -37.50% and 11.71%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Omega Therapeutics, Inc. (OMGA) Surges 19.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Omega Therapeutics, Inc. (OMGA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 14.29% and 4.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Bellicum Pharmaceuticals (BLCM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Bellicum Pharmaceuticals (BLCM) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.